High-sensitivity cardiac troponin T and the risk of heart failure in postmenopausal women of the ARIC Study.
Journal
Menopause (New York, N.Y.)
ISSN: 1530-0374
Titre abrégé: Menopause
Pays: United States
ID NLM: 9433353
Informations de publication
Date de publication:
04 01 2021
04 01 2021
Historique:
pubmed:
6
1
2021
medline:
20
3
2021
entrez:
5
1
2021
Statut:
epublish
Résumé
We investigated isolated and joint effects of early menopause (occurrence before 45 y of age) and high-sensitivity cardiac troponin T elevation (hs-cTnT ≥ 14 ng/L) on heart failure (HF) incidence in postmenopausal women. We included 2,276 postmenopausal women, aged 67-90 years, with hs-cTnT measurements and without prevalent HF from the Atherosclerosis Risk in Communities study Visit 5 (2011-2013). Women were categorized according to early menopause and hs-cTnT group. Cox proportional hazards models were used for analysis. Over a median follow-up of 5.5 years, we observed 104 HF events. The incidence rates of HF were greater in women with hs-cTnT elevation when compared to those without hs-cTnT elevation. In unadjusted analysis, the hazard ratios for incident HF were threefold greater in women with hs-cTnT elevation, with or without early menopause, (3.03 [95% CI, 1.59-5.77]) and (3.29 [95% CI, 2.08-5.21]), respectively, but not significantly greater in women with early menopause without hs-cTnT elevation, when compared to women with neither early menopause nor hs-cTnT elevation at Visit 5. After adjusting for HF risk factors and NT-pro B-type natriuretic peptide, these associations were attenuated and became nonsignificant for women with hs-cTnT elevation, but became stronger and significant for women with early menopause without hs-cTnT elevation (2.39 [95% CI, 1.28-4.46]). Irrespective of early menopause status, hs-cTnT elevation is associated with greater HF incidence but this association is partially explained by HF risk factors. Even in the absence of hs-cTnT elevation, early menopause is significantly associated with HF incidence after accounting for HF risk factors. Video Summary:http://links.lww.com/MENO/A693.
Autres résumés
Type: plain-language-summary
(eng)
Video Summary:http://links.lww.com/MENO/A693.
Identifiants
pubmed: 33399316
doi: 10.1097/GME.0000000000001705
pii: 00042192-202103000-00008
doi:
Substances chimiques
Biomarkers
0
Peptide Fragments
0
Troponin T
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
284-291Subventions
Organisme : NHLBI NIH HHS
ID : HHSN268201700001I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700002I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700003I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700005I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700004I
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001860
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL134320
Pays : United States
Informations de copyright
Copyright © 2021 by The North American Menopause Society.
Déclaration de conflit d'intérêts
Financial disclosure/conflicts of interest: None reported.
Références
McEvoy JW, Chen Y, Nambi V, et al. High-sensitivity cardiac troponin T and risk of hypertension. Circulation 2015; 132:825–833.
Pokharel Y, Sun W, Villareal DT, et al. Association between high-sensitivity troponin T and cardiovascular risk in individuals with and without metabolic syndrome: the ARIC study. Eur J Prev Cardiol 2017; 24:628–638.
Seliger SL, Hong SN, Christenson RH, et al. High-sensitive cardiac troponin T as an early biochemical signature for clinical and subclinical heart failure: MESA (Multi-Ethnic Study of Atherosclerosis). Circulation 2017; 135:1494–1505.
Myhre PL, Claggett B, Ballantyne CM, et al. Association between circulating troponin concentrations, left ventricular systolic and diastolic functions, and incident heart failure in older adults. JAMA Cardiol 2019; 4:997–1006.
Rubin J, Matsushita K, Lazo M, et al. Determinants of minimal elevation in high-sensitivity cardiac troponin T in the general population. Clin Biochem 2016; 49:657–662.
Ebong IA, Watson KE, Goff DC, et al. Age at menopause and incident heart failure: the Multi-Ethnic Study of Atherosclerosis. Menopause 2014; 21:585–591.
Rahman I, Akesson A, Wolk A. Relationship between age at natural menopause and risk of heart failure. Menopause 2015; 22:12–16.
Appiah D, Schreiner PJ, Demerath EW, Loehr LR, Chang PP, Folsom AR. Association of age at menopause with incident heart failure: a prospective cohort study and meta-analysis. J Am Heart Assoc 2016; 5: pii: e003769.
pii: e003769
Appiah D, Schreiner PJ, Nwabuo CC, Wellons MF, Lewis CE, Lima JA. The association of surgical versus natural menopause with future left ventricular structure and function: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Menopause 2017; 24:1269–1276.
Lima R, Wofford M, Reckelhoff J. Hypertension in postmenopausal women. Curr Hypertens Rep 2012; 14:254–260.
He L, Tang X, Li N, et al. Menopause with cardiovascular disease and its risk factors among rural Chinese women in Beijing: a population-based study. Maturitas 2012; 72:132–138.
Hutter R, Badimon J, Fuster V, Narula J. Coronary artery disease in aging women: a menopause of endothelial progenitor cells? Med Clin N Am 2012; 96:93–102.
Oliveira P, Carvalho R, Portincasa P, Bonfrate L, Sardao V. Fatty acid oxidation and cardiovascular risk during menopause: a mitochodrial connection? J Lipids 2012; 2012:365798.
Lambrinoudaki I, Armeni E, Georgiopoulos G, et al. Subclinical atherosclerosis in menopausal women with low to medium calculated cardiovascular risk. Int J Cardiol 2013; 164:70–76.
Kallen A, Pal L. Cardiovascular disease and ovarian function. Curr Opin Obstet Gynecol 2011; 23:258–267.
Subramanya V, Zhao D, Ouyang P, et al. Sex hormone levels and change in left ventricular structure among men and post-menopausal women: the Multi-Ethnic Study of Atherosclerosis (MESA). Maturitas 2018; 108:37–44.
Ford I, Shah AS, Zhang R, et al. High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. J Am Coll Cardiol 2016; 68 (25):2719–2728.
The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 1989; 129:687–702.
Rosamond WD, Chambless LE, Heiss G, et al. Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987-2008. Circulation 2012; 125:1848–1857.
McEvoy JW, Lazo M, Chen Y, et al. Patterns and determinants of temporal change in high-sensitivity cardiac troponin-T: the Atherosclerosis Risk in Communities Cohort Study. Int J Cardiol 2015; 187:651–657.
Madan N, Lee AK, Matsushita K, et al. Relation of isolated systolic hypertension and pulse pressure to high-sensitivity cardiac troponin-T and N-terminal pro-B-type natriuretic peptide in older adults (from the Atherosclerosis Risk in Communities study). Am J Cardiol 2019; 124:245–252.
McEvoy JW, Chen Y, Ndumele CE, et al. Six-year change in high-sensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death. JAMA Cardiol 2016; 1:519–528.
Jia X, Sun W, Hoogeveen RC, et al. High-sensitivity troponin I and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study. Circulation 2019; 139 (23):2642–2653.
Matsushita K, Kwak L, Yang C, et al. High-sensitivity cardiac troponin and natriuretic peptide with risk of lower-extremity peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) study. Eur Heart J 2018; 39:2412–2419.
Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol 2008; 101:1016–1022.
Rosamond WD, Chang PP, Baggett C, et al. Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria. Circ Heart Fail 2012; 5:152–159.
Ebong IA, Watson KE, Goff DC, et al. Association of menopause age and N-terminal pro brain natriuretic peptide: the Multi-Ethnic Study of Atherosclerosis. Menopause 2015; 22:527–533.
Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 update: a report from the American Heart Association. Circulation 2020; e139L e596.
Evans JDW, Dobbin SJH, Pettit SJ, Di Angelantonio E, Willeit P. High-sensitivity cardiac troponin and new-onset heart failure: a systematic review and meta-analysis of 67,063 patients with 4,165 incident heart failure events. JACC Heart Failure 2018; 6:187–197.
Lee S-D, Kuo W-W, Ho Y-J, et al. Cardiac Fas-dependent and mitochondria-dependent apoptosis in ovariectomized rats. Maturitas 2008; 61:268–277.
Marques CMM, Nascimento FAM, Mandarim-de-Lacerda CA, Aguila MB. Exercise training attenuates cardiovascular adverse remodeling in adult ovariectomized spontaneously hypertensive rats. Menopause 2006; 13:87–95.
Ying W, Zhao D, Ouyang P, et al. Sex hormones and change in N-terminal pro-B-type natriuretic peptide levels: the Multi-Ethnic Study of Atherosclerosis. J Clin Endocrinol Metab 2018; 103:4304–4314.
Lam CS, Cheng S, Choong K, et al. Influence of sex and hormone status on circulating natriuretic peptides. J Am Coll Cardiol 2011; 58:618–626.
Glisic M, Rojas LZ, Asllanaj E, et al. Sex steroids, sex hormone-binding globulin and levels of N-terminal pro-brain natriuretic peptide in postmenopausal women. Int J Cardiol 2018; 261:189–195.
Agarwala A, Michos ED, Samad Z, Ballantyne CM, Virani SS. The use of sex-specific factors in the assessment of women's cardiovascular risk. Circulation 2020; 141:592–599.
Ebong IA, Goff DC Jr, Rodriguez CJ, Chen H, Bertoni AG. Mechanisms of heart failure in obesity. Obes Res Clin Pract 2014; 8:e540–e548.
Kok HS, van Asselt KM, van der Schouw YT, et al. Heart disease risk determines menopausal age rather than the reverse. J Am Coll Cardiol 2006; 47:1976–1983.
Wellons M, Ouyang P, Schreiner P, Herrington D, Vaidya D. Early menopause predicts future coronary heart disease and stroke: the Muti-Ethnic Study of Atherosclerosis. Menopause 2012; 19:1081–1087.
Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol 2016; 13:368–378.
Liu L, Klein L, Eaton C, et al. Menopausal hormone therapy and risks of first hospitalized heart failure and its subtypes during the intervention and extended postintervention follow-up of the Women's Health Initiative Randomized Trials. J Card Fail 2020; 26:2–12.
Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345:e6409.
Chang H, Odongua N, Ohrr H, Sull J, Nam C. Reproductive risk factors for cardiovascular mortality among postmenopausal women in Korea: the Kangwha Cohort Study, 1985-2005. Menopause 2011; 18:1205–1212.
Bachmann G. Physiologic aspects of natural and surgical menopause. The Journal of Reproductive Medicine 2001; 46: (suppl 3): 307–315.
Korse CM, Bonfrer JM, van Beurden M, Verheijen RH, Rookus MA. Estradiol and testosterone levels are lower after oophorectomy than after natural menopause. Tumour Biol 2009; 30:37–42.